CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 8 enrolled
Drug / intervention
Exenatidedrug
Likely dose
Exenatide 5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00650546
NCT00650546Phase 3Completed
CompareCT.gov

Role of Exenatide in Treatment of NASH-a Pilot Study

Indiana University·interventional·Posted Apr 1, 2008·Updated Apr 11, 2017

In Brief

A Phase 3 clinical trial evaluating Exenatide for Nonalcoholic Fatty Liver Disease. Completed, enrolled 8 participants across 3 sites.

Detailed Summary

We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Fatty Liver Disease
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 1, 2008
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.3 years ago

Interventions

Exenatidedrug

5 mcg twice a day titrated to 10 mcg twice a day